Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...
The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...
Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...
A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.
The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...
Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...
Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market ...
Fintel reports that on December 11, 2025, Stifel maintained coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 20.12% Upside As of December ...
TipRanks on MSN
Alnylam Pharma announces convertible notes buyback
An announcement from Alnylam Pharma ( ($ALNY) ) is now available. On December 10, 2025, Alnylam Pharmaceuticals announced it had entered into ...
Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp ...
The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion market, may have just revealed the first indication of a slowdown. For the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback